0
ARTICLE |

THE POTENCY OF ANTIPNEUMOCOCCIC SERUM

N. E. WAYSON, M.D.; G. W. McCOY, M.D.
JAMA. 1918;70(23):1747-1749. doi:10.1001/jama.1918.02600230017004.
Text Size: A A A
Published online

Antipneumococcic serum, as developed by Neufeld, was not regarded as entirely satisfactory as a therapeutic agent. Cole and his co-workers renewed the interest in this serum, however, by their work on the differentiation of types of pneumococci and the application of the specific univalent serums.

Clinical evidence has since accumulated which tends to encourage the use of Cole's Type I serum in cases in which the corresponding type of infecting organism has been determined.

The official control of this product by protection tests has thus far been confined to serum produced by the immunization of horses against Type I pneumococci.

Polyvalent serums are required to show the same protective action against Type I organisms as is the specific type serum.

The evidences of the manufacturers' protection tests are accepted for the potency of serums made by immunizing animals against pneumococci of Types II and III.

The present method of testing

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs